KEYNOTE-177 Final Analysis: First-line Pembrolizumab vs Chemotherapy in MSI-H/dMMR Metastatic CRC

June 4-8, 2021; Online at https://conferences.asco.org/am
In the final analysis from KEYNOTE-177, first-line pembrolizumab was associated with an improved median OS compared with chemotherapy in patients with MSI-H/dMMR mCRC.
Format: Microsoft PowerPoint (.ppt)
File Size: 509 KB
Released: June 17, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Related Content

Downloadable clinical resource with practical guidance on preventative care plans for transgender patients, from Clinical Care Options (CCO)

Nelson F. Sanchez, MD
Program Director
Released: October 7, 2022

Expert analysis module on key data from ESMO World GI 2022 in gastrointestinal cancers, from Clinical Care Options (CCO)

Joleen Hubbard, MD Rachna Shroff, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: October 4, 2022 Expired: October 3, 2023

An expert nurse practitioner provides guidance on strategies for developing compassionate care plans with transgender patients based on their current anatomy

person default Lauren Radziejewski, DNP Physicians: maximum of 0.75 AMA PRA Category 1 Credits Registered Nurses: 0.75 Nursing contact hours Pharmacists: 0.75 contact hours (0.075 CEUs) Released: October 4, 2022 Expired: October 3, 2023

Download this expert slideset on strategies for developing compassionate care plans with transgender patients based on their current anatomy

person default Lauren Radziejewski, DNP Released: October 4, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings